Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.

Antiviral research - 1 Aug 2011

Binder Joseph, Tetangco Selwyna, Weinshank Megan, Maegley Karen, Lingardo Laura, Diehl Wade, Love Robert, Patick Amy K, Smith George J

Abstract excerpt

Several potent inhibitors of hepatitis C virus (HCV) NS3/4A protease have been identified that show great clinical potential against genotype 1. Due to the tremendous genetic diversity that exists among HCV isolates, development of broad spectrum inhibitors is challenging. With a limited number o...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Fluorescence Resonance Energy Transfer
Share to Macrocyclic Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protease Inhibitors

Share to Quinolines

Share to Replicon

Share to Sequence Analysis, Protein

Share to Thiazoles

Source

Identifiers

PMID: 21620899
DOI: 10.1016/j.antiviral.2011.05.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21620899-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.PMID 21620899Read ↗

Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.Semantic proximity Read ↗

Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells.Semantic proximity Read ↗

In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.Semantic proximity Read ↗

Development of robust hepatitis C virus genotype 4 subgenomic replicons.Semantic proximity Read ↗

Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.Semantic proximity Read ↗

Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolatesSemantic proximity Read ↗

Screening of hepatitis C virus inhibitors using genotype 1a HCV replicon cell lines.Semantic proximity Read ↗

Novel chimeric genotype 1b/2a hepatitis C virus suitable for high-throughput screening.Semantic proximity Read ↗

Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems.Semantic proximity Read ↗

Replication-competent chimeric hepatitis C virus subgenomic replicons.Semantic proximity Read ↗

Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus.Semantic proximity Read ↗

A transient cell-based phenotype assay for hepatitis C NS3/4A protease: application to potency determinations of a novel macrocyclic inhibitor against diverse protease sequences isolated from plasma infected with HCV.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.